Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Capricor Therapeutics Community
NasdaqCM:CAPR Community
1
Narratives
written by author
0
Comments
on narratives written by author
24
Fair Values set
on narratives written by author
Community Investing Ideas
Capricor Therapeutics
Popular
Undervalued
Overvalued
Capricor Therapeutics
AN
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
Future FDA Approvals Will Expand Rare Disease Treatments
Key Takeaways Strong pipeline in rare disease therapies and advanced platforms positions Capricor for regulatory support, market demand, and diversified future revenue streams. Solid financial position and manufacturing readiness reduce dilution risk, enabling quicker commercialization and improved earnings stability.
View narrative
US$20.60
FV
61.4% undervalued
intrinsic discount
115.71%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
15
users have followed this narrative
about 22 hours ago
author updated this narrative
Your Valuation for
CAPR
CAPR
Capricor Therapeutics
Your Fair Value
US$
Current Price
US$7.96
214.6% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-90m
97m
2015
2018
2021
2024
2025
2027
2030
Revenue US$97.3m
Earnings US$20.3m
Advanced
Set Fair Value